# Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

> **NCT07024680** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 150 (estimated)

## Conditions studied

- Papillary Renal Cell Carcinoma

## Interventions

- **OTHER:** Observational, None intervention

## Key facts

- **NCT ID:** NCT07024680
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2026-07-14
- **Final completion:** 2026-07-14
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024680, "Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07024680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*